Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
21 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Maintenance antihormones, hormones, and glucocorticoids.
Patients must have:
Histologically proven metastatic cancer including Kaposi's sarcoma and lymphoproliferative disorders to the skin or cutaneous sites. NOTE:
Primary basal or squamous cell cancer of the skin is allowed.
Failed both primary and secondary chemotherapy and/or immunotherapy protocols.
Measurable skin or cutaneous lesions. 4 Life expectancy of at least 20 weeks.
Prior therapy for cutaneous lesions from Kaposi's sarcoma or lymphoproliferative disorders.
Prior maintenance steroids and hormone/antihormone therapy.
Patients with the following symptoms or conditions are excluded:
Active infections other than medically stable HIV infection.
Active congestive heart failure, any persistent arrhythmia or transient serious arrhythmia (ventricular tachycardia, sinoatrial arrest, etc.), or progressive cardiomyopathy.
Unstable blood pressure.
Seizures or other CNS disorders.
Severe unstable diabetes mellitus.
Any other medical conditions that would prevent completion of study or produce significant risk to patient.